(HealthDay News) — Certain genetic variants may modify bladder cancer prognosis, according to a study published online March 26 in BJU International.
Angeline S. Andrew, PhD, from the Geisel School of Medicine in Lebanon, NH, and colleagues examined genetic variants hypothesized to modify bladder cancer prognosis in a cohort of 563 patients with urothelial-cell carcinoma.
Participants were followed after diagnosis to ascertain recurrence and survival status, and the correlations between single nucleotide polymorphisms (SNPs) and prognosis end points were assessed.
The researchers identified shorter time to first recurrence for patients with aldehyde dehydrogenase 2 variants (adjusted non-invasive hazard ratio, 1.90).
Patients with non-invasive tumors heterozygous for DNA repair X-ray cross-complementing protein 4 genotype had longer survival than those with wild-type genotype (adjusted hazard ratio, 0.53).
Patients with a variant allele in vascular cellular adhesion molecule 1 who were treated with immunotherapy had shorter time to recurrence (P interaction < 0.001).
“Our analysis suggests candidate prognostic SNPs that could guide personalized bladder cancer surveillance and treatment,” the researchers wrote.